uniQure N.V. Form 8-K Summary
Reporting date: September 29, 2026. The filing reports an update on ongoing clinical trials of AMT-130. It is a current report, not a periodic financial-results filing.
Financial and operating metrics
The supplied filing text contains no revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Clinical update and material changes
uniQure says it presented an update on its ongoing AMT-130 clinical trials and issued a press release summarizing the presentation. The presentation and release are identified as Exhibits 99.1 and 99.2, but their contents are not included in the supplied text. Accordingly, trial results and changes versus prior updates cannot be assessed from this text.
Outlook, risks, and contingencies
No specific guidance, outlook, risks, or contingencies are described in the supplied text. The company states that the Item 7.01 information and exhibits are furnished, not filed for specified liability purposes, and are not incorporated by reference into other SEC filings.
Investor verification checklist
- Review Exhibits 99.1 and 99.2 for AMT-130 trial data, timelines, and management commentary.
- Verify whether the update describes any safety findings, regulatory interactions, or changes to planned studies.
- Consult the company’s financial filings for current financial position and liquidity information, which this 8-K does not provide.